Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term double-blind. Found 11 abstracts

Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao LC, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma. European Urology. 2012 Dec;62(6):1013-9.   PMCID: No NIH
Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Annals of Oncology. 2011 Apr;22(4):939-46.   PMCID: not NIH funded
Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen JH, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. European Journal of Cancer. 2011 Dec;47(18):2706-14.   PMCID: not NIH funded
Mortimer JE, Barsevick AM, Bennett CL, Berger AM, Cleeland C, DeVader SR, Escalante C, Gilreath J, Hurria A, Mendoza TR, Rugo HS. Studying Cancer-Related Fatigue: Report of the NCCN Scientific Research Committee. Journal of the National Comprehensive Cancer Network. 2010 Dec;8(12):1331-9.   PMCID: not NIH funded
Zbrozek AS, Hudes G, Levy D, Strahs A, Berkenblit A, DeMarinis R, Parasuraman S. Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma. PharmacoEconomics. 2010 Jan;28(7):577-84.   PMCID: not NIH funded
Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 2009 Sep;27(27):4462-8.   PMCID: not NIH funded
Crawford J, Kosmidis PA, Hirsch FR, Langer CJ. Targeting anemia in patients with lung cancer. JOURNAL OF THORACIC ONCOLOGY. 2006 Sep;1(7):716-25.
Levy MH, Samuel TA. Management of cancer pain. Seminars in Oncology. 2005 Apr;32(2):179-93.
Tapiero H, Ba GN, Couvreur P, Tew KD. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomedicine & Pharmacotherapy. 2002 Jul;56(5):215-22.
Ge Y, Grossman RI, Udupa JK, Fulton J, Constantinescu CS, Gonzales-Scarano F, Babb JS, Mannon LJ, Kolson DL, Cohen JA. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS - Quantitative MR assessment. Neurology. 2000 Feb 22;54(4):813-7.
Abrams DB, Orleans CT, Niaura RS, Goldstein MG, Prochaska JO, Velicer W. Integrating individual and public health perspectives for treatment of tobacco dependence under managed health care: A combined stepped-care and matching model. Annals of Behavioral Medicine. 1996 Jan;18(4):290-304.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term double-blind

double-blind placebo-controlled trial quality-of-life interferon-alpha trial phase-iii iii trial breast-cancer Cancer-related fatigue moderately emetogenic transdermal fentanyl coronary heart-disease smoking cessation program nausea epoetin-alpha status scale score ABT-869 of-life prostaglandins Angiogenesis inhibitors fatigue assessment inhibitor nonplatinum chemotherapy patients receiving chemotherapy resonance serial VEGFR ondansetron darbepoetin-alpha omega-3 PUFA transmucosal fentanyl citrate sunitinib fuzzy-connectedness nonsteroidal antiinflammatory drugs docosahexaenoic acid lung cancer activity hemoglobin Renal cell carcinoma efficacy metaanalysis inoperable bowel obstruction cigarette-smoking chemotherapy treatable contributing therapy pain disability mutations methylphenidate factors to fatigue temsirolimus placebo quit-smoking antitumor-activity extrinsic motivation MR survival transdermal nicotine patch epoetin alfa sorafenib preference low-dose ketamine quantification high-dose melphalan blood-pressure glatiramer acetate induced emesis factor receptor myeloma neuropathic pain erythropoietin relapsing-remitting MS papillary multicenter stop-smoking community oncology depression enhancing lesions cancer transfusion requirements expression palonosetron activated protein-kinase volume measurement release morphine formulation carcinoma time plus chemotherapy-induced nausea solid tumors phase-iii trial magnetic- fish-oil randomized cyclooxygenases spontaneously hypertensive rats anemia Sunitinib Sunitinib Non-clear cell renal cell carcinoma-Targeted therapy-Renal cell carcinoma variant histology-Papillary renal cell carcinoma-Chromophobe renal cell carcinoma expanded disability disease- interleukin-2 dexamethasone cost-effectiveness analysis quality-adjusted survival consensus conference alpha-linolenic acid endothelial growth-factor cardiovascular met protooncogene 5-ht3 receptor fagerstrom tolerance questionnaire multiple-sclerosis phantom limb pain dietary eicosapentaenoic acid
Last updated on Wednesday, February 05, 2020